BRIEF published on 09/16/2026 at 22:05, 8 hours 4 minutes ago Innate Pharma and Sobi formalize their partnership Strategic Partnership Innate Pharma Phase 3 TELLOMAK-3 Sobi T-cell Lymphomas
BRIEF published on 09/16/2026 at 22:05, 8 hours 4 minutes ago Innate Pharma and Sobi Partnership Becomes Effective Innate Pharma Lacutamab Sobi Partnership TELLOMAK-3 Study T-cell Lymphoma
PRESS RELEASE published on 09/16/2026 at 22:00, 8 hours 9 minutes ago Inside Information / Other news releases Innate Pharma and Sobi partnership becomes effective after meeting closing conditions, triggering USD 75 million payment and commencing TELLOMAK-3 Phase 3 study in Q1 2027 Partnership Innate Pharma Closing Conditions Sobi TELLOMAK-3
BRIEF published on 09/10/2026 at 07:05, 6 days 23 hours ago Innate Pharma to Provide Financial Insights in Upcoming Conference Call Conference Call Business Strategy Financial Update Innate Pharma 2026 Results
BRIEF published on 09/10/2026 at 07:05, 6 days 23 hours ago Innate Pharma announces a conference on its half-year results Financial Results Conference Call Immunotherapy Innate Pharma Biopharmaceutical Partnerships
PRESS RELEASE published on 09/10/2026 at 07:00, 6 days 23 hours ago Inside Information / Other news releases Innate Pharma to host conference call on September 17, 2026, providing first half 2026 financial results and business update. Event details available on www.innate-pharma.com Financial Results Conference Call Biotechnology Business Update Innate Pharma
BRIEF published on 08/14/2026 at 11:35, 1 month 2 days ago Innate Pharma Announces Upcoming Conference Call and Webcast Conference Call Biotechnology Webcast Immunotherapy Innate Pharma
PRESS RELEASE published on 08/14/2026 at 11:30, 1 month 2 days ago Inside Information / Other news releases Innate Pharma to host conference call and webcast with key executives discussing latest updates. Event details available on company website Conference Call Biotechnology Webcast Immunotherapy Innate Pharma
BRIEF published on 08/14/2026 at 10:32, 1 month 2 days ago Innate Pharma Announces €30 Million Share Offering Biotechnology Investment Share Offering Innate Pharma ADC Portfolio
PRESS RELEASE published on 08/14/2026 at 10:27, 1 month 2 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Innate Pharma prices €30 million offering of Ordinary Shares at €1.70 per share in Marseille, France. Proceeds will fund clinical development and ADC portfolio advancement Ordinary Shares Clinical Development Offering Innate Pharma ADC Portfolio
Published on 09/16/2026 at 23:45, 6 hours 24 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 8 hours 39 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 13 hours 14 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 15 hours 9 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 16 hours 9 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/17/2026 at 04:25, 1 hour 44 minutes ago Zhou Jianjun from Huawei: Building a Grid-Interactive AIDC Solution to Maximize Tokens Per Watt
Published on 09/16/2026 at 23:45, 6 hours 24 minutes ago WESCAN GOLDFIELDS COMMENCES UAV MAGNETIC AND LIDAR SURVEYS AT MUNRO LAKE PROJECT
Published on 09/16/2026 at 22:33, 7 hours 35 minutes ago EQS-Adhoc: Bilfinger adjusts outlook for 2026 and resolves program “Agile”
Published on 09/16/2026 at 21:15, 8 hours 54 minutes ago Gastech 2026 in Bangkok Converts Global Energy Ambition into Billions of Dollars in Deals
Published on 09/16/2026 at 20:27, 9 hours 42 minutes ago EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 17:45, 12 hours 24 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 23 hours 9 minutes ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 12 hours ago Report on the Combined General Meeting of the 10th of September 2026
